MARKET DEFINITION  

Psychedelic drugs commonly referred to as simply hallucinogens are a class of chemicals that are typically consumed recreationally to alter and improve sensory perceptions, mental processes, and energy levels as well as to promote spiritual experiences. They include substances like LSD as well as plants like peyote. Psychedelics are frequently consumed orally, smoked (and inhaled), or made into tea. Many societies have utilized hallucinogens for centuries, and some are still employed today in religious rituals to achieve altered states of consciousness or spiritual experiences. In the 1960s, hallucinogens were utilized in psychotherapy, but this practice was discontinued until very recently for primarily political reasons. Since then, psychedelic drug use in psychological experimentation has been revitalized by psychology research.

MARKET DYNAMICS  

Psychedelics are quietly making a resurgence in psychology and psychiatry as a successful treatment for illnesses like anxiety, depression, post-traumatic stress disorder (PTSD), and Others. Regulated treatments, however, are still in the experimental stage and are not widely available. By understanding the mechanisms of action of psychedelics concerning their effects on receptor subsystems, systems-level brain activity, connectivity, and cognitive and emotional processing, state-of-the-art research have lately started to bridge significant knowledge gaps. Furthermore, according to functional research, psychedelics may have therapeutic benefits by altering how one experiences oneself, how one processes emotions, and how one thinks about others. These findings offer a scientific framework for exploring and using psychedelic substances in psychiatry.

REPORT SCOPE  

The report titled “Global Psychedelic Drugs Market – Size, Share, Growth, Opportunities, and Competitive Analysis, 2022 – 2028” offers strategic visions into the global Psychedelic Drugs market along with the market size (Value in “US$ Mn”) for the historical period 2017 to 2021 and estimates for the forecast period 2022 to 2028. The RI report is an in-depth study of the global Psychedelic Drugs market with a strong focus on key market trends, vital player strategies, and market forecasts. The study also covers key market dynamics, including drivers, restraints, opportunities, challenges, and existing and upcoming pathways that help CXOs make critical business decisions effectively. The global Psychedelic Drugs Market is predicted to grow at a significant CAGR over the forecast period from 2022 to 2028.

GEOGRAPHICAL OVERVIEW  

The research report includes a detailed overview of the industry comprising quantitative and qualitative information. It gives a broad overview of the worldwide market forecasts for major segments. It also includes market size and forecast projections for five key regions: North America, Europe, Asia-Pacific (APAC), South America, and the Middle East & Africa (MEA), for the years 2017 to 2028. The market is further divided by categories and countries within each province. The research scrutinizes and forecasts over 20 nations worldwide, as well as the present trend and possibilities in these regions.

MARKET SEGMENTATION  

The Global Psychedelic Drugs Market is segmented based on Source, End User, Sales Channel, and region. Based on Source, the market has been segmented into Synthetic & Natural, whereas based on End Users, the market comprises Hospitals, Specialty Clinics, Homecare, and Others. Based on Sales Channel, the market has been segmented into Hospitals Pharmacy, Retail Pharmacy, and Online Pharmacy

COMPETITION LANDSCAPE  

The RI research report discusses noteworthy developments in the industry as well as organic and inorganic growth strategies being adopted by the Psychedelic Drugs market players. The report covers industry activities, including new product launches, mergers & acquisitions, business partnerships, and various expansion initiatives being undertaken by the active players in the market. These developments pave the path for various market participants to strengthen their positioning as well as expand their consumer base. The positive market outlook for the global Psychedelic Drugs market is anticipated to present lucrative growth opportunities to the market players. The report also offers detailed profiles of major players in the global Psychedelic Drugs market, emphasizing the strategic initiatives, financial information, SWOT analysis, and key development in the Psychedelic Drugs industry in the past three years.

Key players in the Global Psychedelic Drugs Market have adopted various organic as well as inorganic growth strategies to strengthen their market positioning. Prominent players in the market include:

• Jazz Pharmaceuticals, Inc.
• Janssen Global Services, LLC (a subsidiary of Johnson & Johnson Services, Inc.)
• Hikma Pharmaceuticals PLC
• COMPASS
• Verrian
• Pfizer Inc.
• Hoffmann-La Roche Ltd
• Avadel
• Celon Pharma SA.
• Cybin Corp.
• GH Research
• Entheon Biomedical Corp
• PharmaTher Holdings Ltd.
• NRx Pharmaceuticals, Inc.

COVID-19 IMPACT ANALYSIS ON GLOBAL PSYCHEDELIC DRUGS MARKET

The COVID-19 pandemic is still a very personal, individual experience that is also a once-in-a-lifetime worldwide phenomenon with far-reaching consequences. The epidemic has wreaked havoc on people's lives in all nations and communities and also had a negative impact on global economic development in 2020, unlike anything seen in almost a century. The pandemic severely impacted key economies such as India, Brazil, the U.S., France, Russia, the UK, Italy, Turkey, and Argentina. According to estimates, the virus slowed global economic growth by -3.4 percent to -7.6 percent in 2020, with a rebound of 4.2 percent to 5.6 percent expected in 2021. In 2020, global commerce was expected to decline by 5.3 percent, but it is expected to rise by 8.0 percent in 2021.

In contrast to the global economic downturn in the first half of 2020, the economy began to showcase symptoms of a two-track recovery post the second quarter of 2020, with a fledgling rebound in developed nations, however, slower growth in emerging economies. The outbreak of the Covid-19 pandemic has not only resulted in halted production activity but has also disrupted the global supply chain. The research goes on to evaluate the current and future implications of the COVID-19 pandemic both on the target as well as broader market, thereby, providing accurate and trustworthy forecasts.

RESEARCH PROGRAM DESIGN

KEY QUESTIONS ANSWERED

1. What is the current size of the global Psychedelic Drugs market?
2. What will be the growth rate of the market over the forecast period?
3. Who are the key manufacturers/vendors in the Psychedelic Drugs market space?
4. What are the major market opportunities and market risks faced by the market?
5. What is the impact of COVID-19 on the market?
6. What are the revenue, sales, and price analysis of the top manufacturers in this market?
7. What are the key outcomes of Porter's five forces model?
8. Who are the distributors, traders, and vendors in the industry?

REASONS FOR BUYING THIS REPORT:  

• The report offers comprehensive data on the Psychedelic Drugs market elaborating on the current state and future growth prospects both globally and regionally
• It offers a six-year market forecast trend evaluating the impact of drivers and restraints and supporting factors for growth
• The report offers deep-dive insights into each market segment and critical factors responsible for its growth
• The report presents precise picture of the dynamic competitive landscape which helps our client advance their market position
• The comprehensive analysis of the market along with the inclusion of analyst recommendations ensures that our clients make informed business decisions
• Cross-segment country-level analysis included in the report which provides granular analysis of more than 20+ countries covered in the report scope
• The study includes detailed profiles of major manufacturers to help our readers gain holistic overview of the market competitors and consequently align their business strategies

Chapter 1. Executive Summary
1.1. Market Outlook
1.2. Market Segment Outlook
1.3. Geography Outlook
1.4. Absolute $ Opportunity

Chapter 2. Research Methodology
2.1. Research Approach
2.2. Scope, Definition, and Assumptions
2.3. Data Sources
2.3.1. Secondary Sources
2.3.1.1. Preliminary Data Mining
2.3.2. Primary Sources
2.3.2.1. Statistical Sales Channel
2.3.2.2. Data Triangulation
2.3.2.3. Research Objective

Chapter 3. Market Outlook
3.1. Introduction
3.2. Key Trends
3.2.1. Source Trends
3.2.2. End User Trends
3.2.3. Sales Channel Trends
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Impact Analysis of Market Drivers
3.3.2. Market Restraints
3.3.2.1. Impact Analysis of Market Restraints
3.3.3. Market Opportunities
3.3.3.1. Impact Analysis of Market Opportunities
3.3.4. Market Challenges
3.3.4.1. Impact Analysis of Market Challenges
3.4. Porter’s Five Forces’ Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of New Entrant
3.4.4. Threat of Substitutes
3.4.5. Competitive Rivalry
3.5. Value Chain Analysis: Global Psychedelic Drugs Market
3.6. COVID-19 Impact Assessment in Psychedelic Drugs Market
3.6.1. Impact Assessment on Global Psychedelic Drugs Market
3.6.2. Market Trends and Opportunities in the Covid-19 Landscape

Chapter 4. Global Psychedelic Drugs Market Overview, By Source, 2017 - 2028 (USD Million)
4.1. Global Psychedelic Drugs Market Share, By Source, 2017 - 2028 (USD Million)
4.1.1. Synthetic
4.1.2. Natural

Chapter 5. Global Psychedelic Drugs Market Overview, By End User, 2017 - 2028 (USD Million)
5.1. Global Psychedelic Drugs Market Share, By End User, 2017 - 2028 (USD Million)
5.1.1. Hospitals
5.1.2. Specialty Clinics
5.1.3. Homecare
5.1.4. Others

Chapter 6. Global Psychedelic Drugs Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
6.1. Global Psychedelic Drugs Market Share, By Sales Channel, 2017 - 2028 (USD Million)
6.1.1. Hospitals Pharmacy
6.1.2. Retail Pharmacy
6.1.3. Online Pharmacy

Chapter 7. Global Psychedelic Drugs Market Overview, By Geography, 2017 - 2028 (USD Million)
7.1. Global Psychedelic Drugs Market Share, By Geography, 2017 - 2028 (USD Million)
7.1.1. Market End User and Projections, by Countries, 2017 - 2028 (USD Million)
7.1.2. Market Share and CAGR Comparison, by Countries, 2021 (%)

Chapter 8. North America Psychedelic Drugs Market Overview, By Countries, 2017 - 2028 (USD Million)
8.1. North America Psychedelic Drugs Market Overview, 2017 - 2028 (USD Million)
8.1.1. Market End User and projections, 2017 - 2028 (USD Million)
8.1.2. North America Psychedelic Drugs Market Overview, By Source, 2017 - 2028 (USD Million)
8.1.3. North America Psychedelic Drugs Market Overview, By End User, 2017 - 2028 (USD Million)
8.1.4. North America Psychedelic Drugs Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
8.2. North America Psychedelic Drugs Market Overview, By Countries, 2017 - 2028 (USD Million)
8.2.1. U.S. Psychedelic Drugs Market Overview, 2017 - 2028 (USD Million)
8.2.1.1. U.S. Psychedelic Drugs Market Overview, By Source, 2017 - 2028 (USD Million)
8.2.1.2. U.S. Psychedelic Drugs Market Overview, By End User, 2017 - 2028 (USD Million)
8.2.1.3. U.S. Psychedelic Drugs Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
8.2.2. Canada Psychedelic Drugs Market Overview, 2017 - 2028 (USD Million)
8.2.2.1. Canada Psychedelic Drugs Market Overview, By Source, 2017 - 2028 (USD Million)
8.2.2.2. Canada Psychedelic Drugs Market Overview, By End User, 2017 - 2028 (USD Million)
8.2.2.3. Canada Psychedelic Drugs Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
8.2.3. Mexico Psychedelic Drugs Market Overview, 2017 - 2028 (USD Million)
8.2.3.1. Mexico Psychedelic Drugs Market Overview, By Source, 2017 - 2028 (USD Million)
8.2.3.2. Mexico Psychedelic Drugs Market Overview, By End User, 2017 - 2028 (USD Million)
8.2.3.3. Mexico Psychedelic Drugs Market Overview, By Sales Channel, 2017 - 2028 (USD Million)

Chapter 9. Europe Psychedelic Drugs Market Overview, By Countries, 2017 - 2028 (USD Million)
9.1. Europe Psychedelic Drugs Market Overview, 2017 - 2028 (USD Million)
9.1.1. Market End User and projections, 2017 - 2028 (USD Million)
9.1.2. Europe Psychedelic Drugs Market Overview, By Source, 2017 - 2028 (USD Million)
9.1.3. Europe Psychedelic Drugs Market Overview, By End User, 2017 - 2028 (USD Million)
9.1.4. Europe Psychedelic Drugs Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
9.2. Europe Psychedelic Drugs Market Overview, By Countries, 2017 - 2028 (USD Million)
9.2.1. Germany Psychedelic Drugs Market Overview, 2017 - 2028 (USD Million)
9.2.1.1. Germany Psychedelic Drugs Market Overview, By Source, 2017 - 2028 (USD Million)
9.2.1.2. Germany Psychedelic Drugs Market Overview, By End User, 2017 - 2028 (USD Million)
9.2.1.3. Germany Psychedelic Drugs Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
9.2.2. France Psychedelic Drugs Market Overview, 2017 - 2028 (USD Million)
9.2.2.1. France Psychedelic Drugs Market Overview, By Source, 2017 - 2028 (USD Million)
9.2.2.2. France Psychedelic Drugs Market Overview, By End User, 2017 - 2028 (USD Million)
9.2.2.3. France Psychedelic Drugs Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
9.2.3. UK Psychedelic Drugs Market Overview, 2017 - 2028 (USD Million)
9.2.3.1. UK Psychedelic Drugs Market Overview, By Source, 2017 - 2028 (USD Million)
9.2.3.2. UK Psychedelic Drugs Market Overview, By End User, 2017 - 2028 (USD Million)
9.2.3.3. UK Psychedelic Drugs Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
9.2.4. Italy Psychedelic Drugs Market Overview, 2017 - 2028 (USD Million)
9.2.4.1. Italy Psychedelic Drugs Market Overview, By Source, 2017 - 2028 (USD Million)
9.2.4.2. Italy Psychedelic Drugs Market Overview, By End User, 2017 - 2028 (USD Million)
9.2.4.3. Italy Psychedelic Drugs Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
9.2.5. Spain Psychedelic Drugs Market Overview, 2017 - 2028 (USD Million)
9.2.5.1. Spain Psychedelic Drugs Market Overview, By Source, 2017 - 2028 (USD Million)
9.2.5.2. Spain Psychedelic Drugs Market Overview, By End User, 2017 - 2028 (USD Million)
9.2.5.3. Spain Psychedelic Drugs Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
9.2.6. NORDIC Psychedelic Drugs Market Overview, 2017 - 2028 (USD Million)
9.2.6.1. NORDIC Psychedelic Drugs Market Overview, By Source, 2017 - 2028 (USD Million)
9.2.6.2. NORDIC Psychedelic Drugs Market Overview, By End User, 2017 - 2028 (USD Million)
9.2.6.3. NORDIC Psychedelic Drugs Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
9.2.7. Russia and CIS Psychedelic Drugs Market Overview, 2017 - 2028 (USD Million)
9.2.7.1. Russia and CIS Psychedelic Drugs Market Overview, By Source, 2017 - 2028 (USD Million)
9.2.7.2. Russia and CIS Psychedelic Drugs Market Overview, By End User, 2017 - 2028 (USD Million)
9.2.7.3. Russia and CIS Psychedelic Drugs Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
9.2.8. Rest of Europe Psychedelic Drugs Market Overview, 2017 - 2028 (USD Million)
9.2.8.1. Rest of Europe Psychedelic Drugs Market Overview, By Source, 2017 - 2028 (USD Million)
9.2.8.2. Rest of Europe Psychedelic Drugs Market Overview, By End User, 2017 - 2028 (USD Million)
9.2.8.3. Rest of Europe Psychedelic Drugs Market Overview, By Sales Channel, 2017 - 2028 (USD Million)

Chapter 10. Asia Pacific Psychedelic Drugs Market Overview, By Countries, 2017 - 2028 (USD Million)
10.1. Asia Pacific Psychedelic Drugs Market Overview, 2017 - 2028 (USD Million)
10.1.1. Market End User and projections, 2017 - 2028 (USD Million)
10.1.2. Asia Pacific Psychedelic Drugs Market Overview, By Source, 2017 - 2028 (USD Million)
10.1.3. Asia Pacific Psychedelic Drugs Market Overview, By End User, 2017 - 2028 (USD Million)
10.1.4. Asia Pacific Psychedelic Drugs Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
10.2. Asia Pacific Psychedelic Drugs Market Overview, By Countries, 2017 - 2028 (USD Million)
10.2.1. India Psychedelic Drugs Market Overview, 2017 - 2028 (USD Million)
10.2.1.1. India Psychedelic Drugs Market Overview, By Source, 2017 - 2028 (USD Million)
10.2.1.2. India Psychedelic Drugs Market Overview, By End User, 2017 - 2028 (USD Million)
10.2.1.3. India Psychedelic Drugs Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
10.2.2. China Psychedelic Drugs Market Overview, 2017 - 2028 (USD Million)
10.2.2.1. China Psychedelic Drugs Market Overview, By Source, 2017 - 2028 (USD Million)
10.2.2.2. China Psychedelic Drugs Market Overview, By End User, 2017 - 2028 (USD Million)
10.2.2.3. China Psychedelic Drugs Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
10.2.3. Japan Psychedelic Drugs Market Overview, 2017 - 2028 (USD Million)
10.2.3.1. Japan Psychedelic Drugs Market Overview, By Source, 2017 - 2028 (USD Million)
10.2.3.2. Japan Psychedelic Drugs Market Overview, By End User, 2017 - 2028 (USD Million)
10.2.3.3. Japan Psychedelic Drugs Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
10.2.4. ASEAN Psychedelic Drugs Market Overview, 2017 - 2028 (USD Million)
10.2.4.1. ASEAN Psychedelic Drugs Market Overview, By Source, 2017 - 2028 (USD Million)
10.2.4.2. ASEAN Psychedelic Drugs Market Overview, By End User, 2017 - 2028 (USD Million)
10.2.4.3. ASEAN Psychedelic Drugs Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
10.2.5. South Korea Psychedelic Drugs Market Overview, 2017 - 2028 (USD Million)
10.2.5.1. South Korea Psychedelic Drugs Market Overview, By Source, 2017 - 2028 (USD Million)
10.2.5.2. South Korea Psychedelic Drugs Market Overview, By End User, 2017 - 2028 (USD Million)
10.2.5.3. South Korea Psychedelic Drugs Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
10.2.6. Australia Psychedelic Drugs Market Overview, 2017 - 2028 (USD Million)
10.2.6.1. Australia Psychedelic Drugs Market Overview, By Source, 2017 - 2028 (USD Million)
10.2.6.2. Australia Psychedelic Drugs Market Overview, By End User, 2017 - 2028 (USD Million)
10.2.6.3. Australia Psychedelic Drugs Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
10.2.7. Rest of Asia Pacific Psychedelic Drugs Market Overview, 2017 - 2028 (USD Million)
10.2.7.1. Rest of Asia Pacific Psychedelic Drugs Market Overview, By Source, 2017 - 2028 (USD Million)
10.2.7.2. Rest of Asia Pacific Psychedelic Drugs Market Overview, By End User, 2017 - 2028 (USD Million)
10.2.7.3. Rest of Asia Pacific Psychedelic Drugs Market Overview, By Sales Channel, 2017 - 2028 (USD Million)

Chapter 11. South America Psychedelic Drugs Market Overview, By Countries, 2017 - 2028 (USD Million)
11.1. South America Psychedelic Drugs Market Overview, 2017 - 2028 (USD Million)
11.1.1. Market End User and projections, 2017 - 2028 (USD Million)
11.1.2. South America Psychedelic Drugs Market Overview, By Source, 2017 - 2028 (USD Million)
11.1.3. South America Psychedelic Drugs Market Overview, By End User, 2017 - 2028 (USD Million)
11.1.4. South America Psychedelic Drugs Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
11.2. South America Psychedelic Drugs Market Overview, By Countries, 2017 - 2028 (USD Million)
11.2.1. Brazil Psychedelic Drugs Market Overview, 2017 - 2028 (USD Million)
11.2.1.1. Brazil Psychedelic Drugs Market Overview, By Source, 2017 - 2028 (USD Million)
11.2.1.2. Brazil Psychedelic Drugs Market Overview, By End User, 2017 - 2028 (USD Million)
11.2.1.3. Brazil Psychedelic Drugs Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
11.2.2. Argentina Psychedelic Drugs Market Overview, 2017 - 2028 (USD Million)
11.2.2.1. Argentina Psychedelic Drugs Market Overview, By Source, 2017 - 2028 (USD Million)
11.2.2.2. Argentina Psychedelic Drugs Market Overview, By End User, 2017 - 2028 (USD Million)
11.2.2.3. Argentina Psychedelic Drugs Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
11.2.3. Rest of South America Psychedelic Drugs Market Overview, 2017 - 2028 (USD Million)
11.2.3.1. Rest of South America Psychedelic Drugs Market Overview, By Source, 2017 - 2028 (USD Million)
11.2.3.2. Rest of South America Psychedelic Drugs Market Overview, By End User, 2017 - 2028 (USD Million)
11.2.3.3. Rest of South America Psychedelic Drugs Market Overview, By Sales Channel, 2017 - 2028 (USD Million)

Chapter 12. Middle East & Africa Psychedelic Drugs Market Overview, By Countries, 2017 - 2028 (USD Million)
12.1. Middle East & Africa Psychedelic Drugs Market Overview, 2017 - 2028 (USD Million)
12.1.1. Market End User and projections, 2017 - 2028 (USD Million)
12.1.2. Middle East & Africa Psychedelic Drugs Market Overview, By Source, 2017 - 2028 (USD Million)
12.1.3. Middle East & Africa Psychedelic Drugs Market Overview, By End User, 2017 - 2028 (USD Million)
12.1.4. Middle East & Africa Psychedelic Drugs Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
12.2. Middle East & Africa Psychedelic Drugs Market Overview, By Countries, 2017 - 2028 (USD Million)
12.2.1. GCC Psychedelic Drugs Market Overview, 2017 - 2028 (USD Million)
12.2.1.1. GCC Psychedelic Drugs Market Overview, By Source, 2017 - 2028 (USD Million)
12.2.1.2. GCC Psychedelic Drugs Market Overview, By End User, 2017 - 2028 (USD Million)
12.2.1.3. GCC Psychedelic Drugs Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
12.2.2. South Africa Psychedelic Drugs Market Overview, 2017 - 2028 (USD Million)
12.2.2.1. South Africa Psychedelic Drugs Market Overview, By Source, 2017 - 2028 (USD Million)
12.2.2.2. South Africa Psychedelic Drugs Market Overview, By End User, 2017 - 2028 (USD Million)
12.2.2.3. South Africa Psychedelic Drugs Market Overview, By Sales Channel, 2017 - 2028 (USD Million)
12.2.3. Rest of Middle East & Africa Psychedelic Drugs Market Overview, 2017 - 2028 (USD Million)
12.2.3.1. Rest of Middle East & Africa Psychedelic Drugs Market Overview, By Source, 2017 - 2028 (USD Million)
12.2.3.2. Rest of Middle East & Africa Psychedelic Drugs Market Overview, By End User, 2017 - 2028 (USD Million)
12.2.3.3. Rest of Middle East & Africa Psychedelic Drugs Market Overview, By Sales Channel, 2017 - 2028 (USD Million)

Chapter 13. Competitive Landscape
13.1. Competitive Environment, 2021
13.2. Strategic Framework
13.2.1. Partnership/Collaborations/Agreement
13.2.2. Expansion
13.2.3. Mergers & Acquisitions
13.2.4. New Product Development

Chapter 14. Key Vendor Analysis
14.1. Jazz Pharmaceuticals, Inc.
14.1.1. Business Overview
14.1.2. Product Benchmarking
14.1.3. Financial Data
14.1.4. Strategic Overview
14.1.5. Key Developments
14.1.6. SWOT Analysis
14.2. Janssen Global Services, LLC (a subsidiary of Johnson & Johnson Services, Inc.)
14.2.1. Business Overview
14.2.2. Product Benchmarking
14.2.3. Financial Data
14.2.4. Strategic Overview
14.2.5. Key Developments
14.2.6. SWOT Analysis
14.3. Hikma Pharmaceuticals PLC
14.3.1. Business Overview
14.3.2. Product Benchmarking
14.3.3. Financial Data
14.3.4. Strategic Overview
14.3.5. Key Developments
14.3.6. SWOT Analysis
14.4. COMPASS
14.4.1. Business Overview
14.4.2. Product Benchmarking
14.4.3. Financial Data
14.4.4. Strategic Overview
14.4.5. Key Developments
14.4.6. SWOT Analysis
14.5. Verrian
14.5.1. Business Overview
14.5.2. Product Benchmarking
14.5.3. Financial Data
14.5.4. Strategic Overview
14.5.5. Key Developments
14.5.6. SWOT Analysis
14.6. Pfizer Inc.
14.6.1. Business Overview
14.6.2. Product Benchmarking
14.6.3. Financial Data
14.6.4. Strategic Overview
14.6.5. Key Developments
14.6.6. SWOT Analysis
14.7. F. Hoffmann-La Roche Ltd
14.7.1. Business Overview
14.7.2. Product Benchmarking
14.7.3. Financial Data
14.7.4. Strategic Overview
14.7.5. Key Developments
14.7.6. SWOT Analysis
14.8. Avadel
14.8.1. Business Overview
14.8.2. Product Benchmarking
14.8.3. Financial Data
14.8.4. Strategic Overview
14.8.5. Key Developments
14.8.6. SWOT Analysis
14.9. Celon Pharma SA.
14.9.1. Business Overview
14.9.2. Product Benchmarking
14.9.3. Financial Data
14.9.4. Strategic Overview
14.9.5. Key Developments
14.9.6. SWOT Analysis
14.10. Cybin Corp.
14.10.1. Business Overview
14.10.2. Product Benchmarking
14.10.3. Financial Data
14.10.4. Strategic Overview
14.10.5. Key Developments
14.10.6. SWOT Analysis
14.11. GH Research
14.11.1. Business Overview
14.11.2. Product Benchmarking
14.11.3. Financial Data
14.11.4. Strategic Overview
14.11.5. Key Developments
14.11.6. SWOT Analysis
14.12. Entheon Biomedical Corp
14.12.1. Business Overview
14.12.2. Product Benchmarking
14.12.3. Financial Data
14.12.4. Strategic Overview
14.12.5. Key Developments
14.12.6. SWOT Analysis
14.13. PharmaTher Holdings Ltd.
14.13.1. Business Overview
14.13.2. Product Benchmarking
14.13.3. Financial Data
14.13.4. Strategic Overview
14.13.5. Key Developments
14.13.6. SWOT Analysis
14.14. NRx Pharmaceuticals, Inc.
14.14.1. Business Overview
14.14.2. Product Benchmarking
14.14.3. Financial Data
14.14.4. Strategic Overview
14.14.5. Key Developments
14.14.6. SWOT Analysis

Chapter 15. Future Outlook of the Market
Disclaimer